Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 148.45 0.27
Bhel 242.00 1.89
Ong Corp 400.05 1.97
Tata Stl 457.10 0.29
Tata Mot 519.45 3.54
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Ajanta Pharma Limited
Ajanta Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532331NSE:AJANTPHARMBloomberg:AJP@INReuters:AJPH.BO
Market Lot: 1Face Value: 5ISIN Demat: INE031B01031
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
28-OCT-13 Ajanta Pharma, a company engaged in manufacturing & marketing of pharmaceutical products, today reported sharp rise of 2.55 times in its net profit to Rs 558.1 million for the quarter ended Sept. 30, 2013 as compared to Rs 218.8 million in the same period last year. 19-SEP-13 Ajanta Pharma announced that the its board of directors has allotted 1,17,16,900 fully paid up shares of Rs 5 each. These shares have been allotted as a part of...   More..
Business Profile Future Plans
CEO Talk
Ajanta Pharma is a typical niche player. The company?s managing director Purushottam Agrawal is confident of Ajanta Pharma logging in a growth of at least 15 per cent in its topline and much higher than that in its bottomline.   Purushottam Agrawal
One To One
Recent news
Latest News
Ajanta Pharma standalone quarterly earnings jump 80.45%   -IRIS 05-Aug-14
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 2807.9010798.708285.00
Other Income86.90177.2074.10
Total Income2894.8010975.908359.10
Cost of goods sold1977.907643.906319.20
OPBDIT916.903332.002039.90
PAT587.202208.601011.20
Gross Block---
Equity capital176.80176.70118.00
EPS (Rs.)-62.8343.17
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-9.95 - 18.738.18 - 18.62
Debt / Equity (x)---
Operating margin (% of OI)31.730.424.4
Net margin (% of OI)20.320.112.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Ajanta House
Charkop
Kandivli (West)
Mumbai
Maharashtra-400 067
PHONE
(022) 6606 1000/ 1204/ 1203
FAX
(022) 6606 1200/ 1300
 
Board of Directors
Board Meetings
Date Purpose
30-OCT-14 Quarterly Results
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer